Neurologists and other health care providers actively involved in the care of patients with multiple sclerosis (MS)
BG-12, Biomarkers, Clinically Isolated Syndrome, Dimethyl Fumurate, Disease-modifying Drugs, Fingolimod, Glatiramer Acetate, MRI, MS Diagnosis, Multiple Sclerosis, Natalizumab, Pegylated Interferon, Radiologically Isolated Syndrome, Teriflunomide
Program Overview/Description of Need: The diagnosis and management of multiple sclerosis (MS) is evolving with the ongoing emergence of disease-modifying drugs (DMDs), newer diagnostic criteria, and MRI measures and biomarkers capable of improving disease surveillance. Combined with a continued push for earlier diagnosis and initiation of DMD therapy, MS diagnosis and management is becoming increasingly complex. Clinicians face more treatment choices, making the formulation of optimal DMD therapies increasingly difficult. In addition, patient concerns with DMD side effects, treatment preferences, drug costs, and other issues continue to negatively impact patient acceptance of and adherence to DMD treatments.
Updating and Advancing the Management of DMD Therapy in Multiple Sclerosis will review the latest research and clinical management information on DMD therapies, diagnostic MRI measures, and biomarkers, in order to provide neurologists and other MS specialists with the knowledge and skills needed to improve the management of patients with MS.
Target Audience: This activity is intended for neurologists and other health care providers actively involved in the care of patients with multiple sclerosis (MS).
DISCLOSURE POLICY STATEMENT
Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.
The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.
The faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Aaron Boster, MD: Advisory Board: Biogen, Genzyme, Medtronic, Novartis, Teva
Suhayl Dhib-Jalbut, MD: Consultant: AbbVie, Bayer, Novartis, Teva, Serono; Grant Support: Novartis, Teva
Aaron E. Miller, MD: Consultant: Acorda Therapeutics, Accordant Health Services (Caremark), Biogen Idec, EMD Serono, Genzyme/Sanofi-Aventis, GlaxoSmithKline, Novartis, Nuron Biotech; Research Support: Acorda Therapeutics, Biogen Idec, Genentech, Genzyme/Sanofi-Aventis, Novartis, Roche, Questcor
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Matthew Horn, MD; Blair St. Amand; Jay Katz, CCMEP; Dana S. Simpler, MD: Nothing to disclose
The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
PHYSICIAN CREDIT DESIGNATION
The Potomac Center for Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
For questions regarding CME credit, the post-test, or evaluation, please email email@example.com.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This continuing medical education activity is jointly provided by the Potomac Center for Medical Education and Rockpointe.
This program is supported by educational grants from Teva Neuroscience, Novartis Pharmaceuticals Corporation, and Bayer Healthcare.
HOW TO RECEIVE CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1.0 AMA PRA category 1 credits™. Statement of credit will be available to print from your user history page.
|Supported Browsers: |
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 5.0+ for Mac OSX 10.5 and above
For video playback, install the latest version of Flash or Quicktime.
|Supported Phones & Tablets: |
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above